Professor Michael Peter Findlay
Michael Findlay completed his undergraduate studies at the University of Otago. He was awarded his Fellowship of the Royal Australasian College of Physicians in 1990 after training in Wellington and Sydney. His post-Fellowship research in the treatment of gastro-intestinal cancers at the Royal Marsden Hospital in London resulted in the awarding of the degree of Doctor of Medicine in 1995. After appointments at Sydney Cancer Centre and Wellington Cancer Centre between 1994 and 2002, he was appointed as the foundation Professor in Oncology at the University of Auckland. With his appointment he established Cancer Trials New Zealand, a clinical trials coordinating centre engaged in the design and conduct of clinical and translational trials in a wide range of cancer types – trials that are considered to be of particular significance to New Zealanders. Other current activities related to cancer and cancer research include: board director and deputy–chairman of the Australasian Gastro-Intestinal Trials Group and its Scientific Advisory Committee; member of the Genesis Oncology Trust Scientific Evaluation Committee, board member of the Auckland Division of the New Zealand Cancer Society; and member of the National Ethics Advisory Committee. Michael is an advocate of research-driven cancer care.
Selected publications and creative works (Research Outputs)
- Hill, A. G., Findlay, M. P., Burge, M. E., Jackson, C., Alfonso, P. G., Samuel, L., ... Jeffery, M. (2018). Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research10.1158/1078-0432.ccr-17-0646
- Gasser, O., Sharples, K. J., Barrow, C., Williams, G. M., Bauer, E., Wood, C. E., ... Jones, J. (2018). A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: Induction of polyfunctional T cells in high-risk melanoma patients. Cancer Immunology, Immunotherapy, 67 (2), 285-298. 10.1007/s00262-017-2085-9
Other University of Auckland co-authors: Geoffrey Williams, Rod Dunbar, Margaret Brimble
- Lawrence, B., Blenkiron, C., Parker, K., Tsai, P., Fitzgerald, S., Shields, P., ... James, S. M. (2017). Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. 10.1101/214585 https://www.biorxiv.org/content/early/2017/11/08/214585.
Other University of Auckland co-authors: Ben Lawrence, Cherie Blenkiron, Kate Parker, Tamsin Robb, Nooriyan Poonawala-Lohani, Braden Woodhouse, Kimi Henare, Marianne Elston, Papaarangi Reid, John Windsor, Andrew MacCormick, Adam Bartlett, Cristin Print
- Muthukaruppan, A., Lasham, A., Blenkiron, C., Woad, K. J., Black, M. A., Knowlton, N., ... Shelling, A. N. (2017). Gene expression profiling of breast tumours from New Zealand patients. New Zealand Medical Journal, 130 (1464), 40-56.
Other University of Auckland co-authors: Annette Lasham, Cherie Blenkiron, Andrew Shelling, Cristin Print, Anita Muthukaruppan
- Wasan, H. S., Gibbs, P., Sharma, N. K., Taieb, J., Heinemann, V., Ricke, J., ... Mills, J. (2017). First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A combined analysis of three multicentre, randomised, phase 3 trials. The Lancet Oncology, 18 (9), 1159-1171. 10.1016/S1470-2045(17)30457-6
- Wilson, M., Mak, W., Firth, M., Deva, S., & Findlay, M. (2017). Mortality within 30 days of systemic anticancer therapy at a tertiary cancer centre: assessing the safety and quality of clinical care. The New Zealand medical journal, 130 (1460), 63-72.
Other University of Auckland co-authors: Michelle Wilson
- Leong, T., Smithers, B. M., Haustermans, K., Michael, M., Gebski, V., Miller, D., ... O’Connell RL (2017). TOPGEAR: A randomized, Phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 24 (8), 2252-2258. 10.1245/s10434-017-5830-6
- Muthukaruppan, A., Lasham, A., Woad, K. J., Black, M. A., Blenkiron, C., Miller, L. D., ... Shelling, A. N. (2017). Multimodal assessment of estrogen receptor mRNA profiles to quantify estrogen pathway activity in breast tumors. Clinical Breast Cancer, 17 (2), 139-153. 10.1016/j.clbc.2016.09.001
Other University of Auckland co-authors: Andrew Shelling, Cristin Print, Annette Lasham, Cherie Blenkiron, Anita Muthukaruppan